NCT06733935 - NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Participants With Immune-Mediated Diseases (Ntrust-2) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 4, 2024

Primary Completion Date

October 31, 2028

Study Completion Date

October 31, 2028

Conditions

Systemic SclerosisIdiopathic Inflammatory MyopathiesAntineutrophil Cytoplasmic Antibody-Associated Vasculitis

Interventions

DRUG

NKX019

NKX019 is an investigational allogeneic CD19-Directed CAR NK

DRUG

Fludarabine

Lymphodepletion

DRUG

Cyclophosphamide

Lymphodepletion

Trial Locations (10)

11794

RECRUITING

Nkarta Investigational Site, Stony Brook

33133

RECRUITING

Nkarta Investigational Site, Miami

48109

RECRUITING

Nkarta Investigational Site, Ann Arbor

60612

RECRUITING

Nkarta Investigational Site, Chicago

66205

RECRUITING

Nkarta Investigational Site, Fairway

75201

RECRUITING

Nkarta Investigational Site, Dallas

77002

RECRUITING

Nkarta Investigational Site, Houston

92868

RECRUITING

Nkarta Investigational Site, Orange

07601

RECRUITING

Nkarta Investigational Site, Hackensack

00674

RECRUITING

Nkarta Investigational Site, Manatí

All Listed Sponsors

lead

Nkarta, Inc.

INDUSTRY